Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.77 |
| ▸ | MC4R | P32245 | 3/20 | 0.73 |
| ▸ | MC5R | P33032 | 2/20 | 0.73 |
| ▸ | MC3R | P41968 | 2/20 | 0.73 |
| ▸ | MC1R | Q01726 | 2/20 | 0.73 |
| ▸ | GLP1R | P43220 | 5/20 | 0.66 |
| ▸ | GCGR | P47871 | 3/20 | 0.65 |
| ▸ | CTSL | P07711 | 3/20 | 0.64 |
| ▸ | CTSS | P25774 | 3/20 | 0.64 |
| ▸ | CTSK | P43235 | 3/20 | 0.64 |
| ▸ | CTSH | P09668 | 1/20 | 0.64 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.60 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.59 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30017682 | 0.98 | C5AR1 (0.77) | C5AR1MC4RMC5RMC3RMC1R | |
| SCHEMBL18388638 | 0.98 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Codactide SCHEMBL29409825 | 0.98 | MC4R (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| SCHEMBL29533861 | 0.98 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| SCHEMBL29430238 | 0.97 | MC4R (0.78) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL522396 | 0.97 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL29383133 | 0.97 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL33366 | 0.97 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL720535 | 0.97 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL29948667 | 0.97 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240307505-A1 | DRUG CONTAINING ADRENOCORTICOTROPIC HORMONE OR DERIVATIVE THEREOF AND USE THEREOF | ZHANG, JING (CN) | 2024-09-19 | — | — | US | claimed |
| EP-4292605-A1 | DRUG CONTAINING ADRENOCORTICOTROPIC HORMONE OR DERIVATIVE THEREOF AND USE THEREOF | Zhang, Jing (CN) | 2023-12-20 | — | — | EP | claimed |
| WO-2022206716-A1 | DRUG CONTAINING ADRENOCORTICOTROPIC HORMONE OR DERIVATIVE THEREOF AND USE THEREOF | 张菁 | 2022-10-06 | — | — | WO | claimed |
| CN-115137809-A | Medicine containing adrenocorticotropic hormone and its derivative and its use | 张菁 | 2022-10-04 | — | — | CN | claimed |
| US-20240309065-A1 | SHORT APOC-II MIMETIC PEPTIDES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2024-09-19 | — | — | US | disclosed |
| US-20240307505-A1 | DRUG CONTAINING ADRENOCORTICOTROPIC HORMONE OR DERIVATIVE THEREOF AND USE THEREOF | ZHANG, JING (CN) | 2024-09-19 | — | — | US | disclosed |
| US-20240165127-A1 | CONTRAST AGENT FOR DIAGNOSIS OF VASCULAR DISEASE CONTAINING GADOLINIUM-BASED COMPOUND AS ACTIVE INGREDIENT AND SYNTHESIS METHOD THEREFOR | DAEGU CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) | 2024-05-23 | — | — | US | disclosed |
| EP-4359432-A2 | SHORT APOC-II MIMETIC PEPTIDES AND METHODS OF USE | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117580857-A | APOC-II short mimetic peptides and methods of use | 美国政府(由卫生和人类服务部的部长所代表) | 2024-02-20 | — | — | CN | disclosed |
| EP-4292605-A1 | DRUG CONTAINING ADRENOCORTICOTROPIC HORMONE OR DERIVATIVE THEREOF AND USE THEREOF | Zhang, Jing (CN) | 2023-12-20 | — | — | EP | disclosed |
| US-11821902-B2 | Quantitative peptide or protein assay | PIERCE BIOTECHNOLOGY, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2022271814-A2 | SHORT APOC-II MIMETIC PEPTIDES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022206716-A1 | DRUG CONTAINING ADRENOCORTICOTROPIC HORMONE OR DERIVATIVE THEREOF AND USE THEREOF | 张菁 | 2022-10-06 | — | — | WO | disclosed |
| EP-4067370-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF PEPTIDES AND PEPTIDE RELATED COMPOUNDS | Yu, Chongxi (US) | 2022-10-05 | — | — | EP | disclosed |
| CN-115137809-A | Medicine containing adrenocorticotropic hormone and its derivative and its use | 张菁 | 2022-10-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240165127-A1 | CONTRAST AGENT FOR DIAGNOSIS OF VASCULAR DISEASE CONTAINING GADOLINIUM-BASED COMPOUND AS ACTIVE INGREDIENT AND SYNTHESIS METHOD THEREFOR | CTRL, CELA1, PRSS1 | C5AR1 474/4885MC4R 4088/4885MC5R 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.